141 research outputs found
Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating alpha-Klotho Concentrations
The CKD-associated decline in soluble α-Klotho levels is considered detrimental. Some in vitro and in vivo animal studies have shown that anti-oxidant therapy can upregulate the expression of α-Klotho in the kidney. We examined the effect of anti-oxidant therapy on α-Klotho concentrations in a clinical cohort with mild tot moderate chronic kidney disease (CKD). We performed a post-hoc analysis of a prospective randomized trial involving 62 patients with mild to moderate CKD (the ATIC study), all using an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for 12 months. On top of that, the intervention group received anti-oxidative therapy consisting of the combination of pravastatin (40 mg/d) and vitamin E (α-tocopherol acetate, 300 mg/d) while the placebo was not treated with anti-oxidants. α-Klotho concentrations were measured at baseline and after 12 months of anti-oxidant therapy. Data were analysed using T-tests and Generalized Estimating Equations, adjusting for potential confounders such as vitamin D, parathyroid hormone, fibroblast-growth-factor 23 (FGF23) and eGFR. The cohort existed of 62 patients with an eGFR (MDRD) of 35 ± 14 ml/min/1.72 m2, 34 were male and mean age was 53.0 ± 12.5 years old. Anti-oxidative therapy did successfully reduce oxLDL and LDL concentrations (P <0.001). α-Klotho concentrations did not change in patients receiving either anti-oxidative therapy (476.9 ± 124.3 to 492.7 ± 126.3 pg/mL, P = 0.23) nor in those receiving placebo 483.2 ± 142.5 to 489.6 ± 120.3 pg/mL, P = 0.62). Changes in α-Klotho concentrations were not different between both groups (p = 0.62). No evidence was found that anti-oxidative therapy affected α-Klotho concentrations in patients with mild-moderate CKD
Can vital signs recorded in patients' homes aid decision making in emergency care? A Scoping Review
Aim: Use of tele-health programs and wearable sensors that allow patients to monitor their own vital signs have been expanded in response to COVID-19. We aimed to explore the utility of patient-held data during presentation as medical emergencies. Methods: We undertook a systematic scoping review of two groups of studies: studies using non-invasive vital sign monitoring in patients with chronic diseases aimed at preventing unscheduled reviews in primary care, hospitalization or emergency department visits and studies using vital sign measurements from wearable sensors for decision making by clinicians on presentation of these patients as emergencies. Only studies that described a comparator or control group were included. Studies limited to inpatient use of devices were excluded. Results: The initial search resulted in 896 references for screening, nine more studies were identified through searches of references. 26 studies fulfilled inclusion and exclusion criteria and were further analyzed. The majority of studies were from telehealth programs of patients with congestive heart failure or Chronic Obstructive Pulmonary Disease. There was limited evidence that patient held data is currently used to risk-stratify the admission or discharge process for medical emergencies. Studies that showed impact on mortality or hospital admission rates measured vital signs at least daily. We identified no interventional study using commercially available sensors in watches or smart phones. Conclusions: Further research is needed to determine utility of patient held monitoring devices to guide management of acute medical emergencies at the patients’ home, on presentation to hospital and after discharge back to the community
Prehospital recognition and antibiotics for 999 patients with sepsis: protocol for a feasibility study
Background: Sepsis is a common condition which kills between 36,000 and 64,000 people every year in the UK.
Early recognition and management of sepsis has been shown to reduce mortality and improve the health and
well-being of people with sepsis. Paramedics frequently come into contact with patients with sepsis and are well
placed to provide early diagnosis and treatment.
We aim to determine the feasibility of undertaking a fully powered randomised controlled trial (RCT) to test the
clinical and cost-effectiveness of paramedics obtaining blood cultures from and administering IV antibiotics to
patients with sepsis, so we can make a decision about whether to proceed to a fully powered randomised
controlled trial, which will answer questions regarding safety and effectiveness for patients and benefit to the
National Health Service (NHS).
Methods/design: This is an individually randomised, two-arm feasibility study for a randomised controlled trial with
a 1:1 ratio. Sixty paramedics will receive training to assist them to recognise sepsis using a screening tool, obtain
blood cultures, and provide IV antibiotics. If sepsis is suspected, paramedics will randomly allocate patients to
intervention or usual care using their next sequential individually issued scratch card. Patients will be followed up at
90 days using linked anonymised data to capture length of hospital admission and mortality. We will also collect
self-reported health-related quality of life (using SF-12) at this time. We will interview ten patients by telephone and
hold a focus group with paramedics, to find out what they think about the intervention.
Discussion: At the end of this study, we will make a recommendation about whether a full randomised controlled
trial of paramedics obtaining blood cultures and administering IV antibiotics for sepsis is warranted, and if so, we
will develop a proposal for research funding in order to take the work forward
Short Keynote Paper: Mainstreaming Personalized Healthcare-Transforming Healthcare Through New Era of Artificial Intelligence
Medicine has entered the digital era, driven by data from new modalities, especially genomics and imaging, as well as new sources such as wearables and Internet of Things. As we gain a deeper understanding of the disease biology and how diseases affect an individual, we are developing targeted therapies to personalize treatments. There is a need for technologies like Artificial Intelligence (AI) to be able to support predictions for personalized treatments. In order to mainstream AI in healthcare we will need to address issues such as explainability, liability and privacy. Developing explainable algorithms and including AI training in medical education are many of the solutions that can help alleviate these concerns
Short Keynote Paper: Mainstreaming Personalized Healthcare-Transforming Healthcare through New Era of Artificial Intelligence
Medicine has entered the digital era, driven by data from new modalities, especially genomics and imaging, as well as new sources such as wearables and Internet of Things. As we gain a deeper understanding of the disease biology and how diseases affect an individual, we are developing targeted therapies to personalize treatments. There is a need for technologies like Artificial Intelligence (AI) to be able to support predictions for personalized treatments. In order to mainstream AI in healthcare we will need to address issues such as explainability, liability and privacy. Developing explainable algorithms and including AI training in medical education are many of the solutions that can help alleviate these concerns
- …